Connection

Daniel Judge to Risk Assessment

Back to Details
This is a "connection" page, showing publications Daniel Judge has written about Risk Assessment.
Daniel Judge
Connection Strength
0.650
Risk Assessment
  1. SSRI/SNRI Therapy is Associated With a Higher Risk of Gastrointestinal Bleeding in LVAD Patients. Heart Lung Circ. 2020 Aug; 29(8):1241-1246.
    View in: PubMed
    Score: 0.106
  2. Performance of the 2015 International Task Force Consensus Statement Risk Stratification Algorithm for Implantable Cardioverter-Defibrillator Placement in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circ Arrhythm Electrophysiol. 2018 02; 11(2):e005593.
    View in: PubMed
    Score: 0.095
  3. Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm. 2013 Nov; 10(11):1661-8.
    View in: PubMed
    Score: 0.070
  4. Incremental value of cardiac magnetic resonance imaging in arrhythmic risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013 Nov 05; 62(19):1761-9.
    View in: PubMed
    Score: 0.069
  5. Shared desmosome gene findings in early and late onset arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Cardiovasc Transl Res. 2010 Dec; 3(6):663-73.
    View in: PubMed
    Score: 0.057
  6. Heart failure and genomics. J Am Coll Cardiol. 2007 Mar 13; 49(10):1106; author reply 1106-7.
    View in: PubMed
    Score: 0.045
  7. Safety and Utility of Cardiopulmonary Exercise Testing in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. J Am Heart Assoc. 2020 02 04; 9(3):e013695.
    View in: PubMed
    Score: 0.027
  8. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. Heart Rhythm. 2019 11; 16(11):e373-e407.
    View in: PubMed
    Score: 0.027
  9. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019 11; 16(11):e301-e372.
    View in: PubMed
    Score: 0.026
  10. Implantable Cardioverter-Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications. J Am Heart Assoc. 2017 Jun 06; 6(6).
    View in: PubMed
    Score: 0.023
  11. Cardiac phenotype and long-term prognosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia patients with late presentation. Heart Rhythm. 2017 06; 14(6):883-891.
    View in: PubMed
    Score: 0.022
  12. Safety of American Heart Association-recommended minimum exercise for desmosomal mutation carriers. Heart Rhythm. 2016 Jan; 13(1):199-207.
    View in: PubMed
    Score: 0.020
  13. Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Eur Heart J. 2016 Mar 01; 37(9):755-63.
    View in: PubMed
    Score: 0.020
  14. Malignant arrhythmogenic right ventricular dysplasia/cardiomyopathy with a normal 12-lead electrocardiogram: a rare but underrecognized clinical entity. Heart Rhythm. 2013 Oct; 10(10):1484-91.
    View in: PubMed
    Score: 0.017
  15. Risk stratification in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. Circ Arrhythm Electrophysiol. 2013 Jun; 6(3):569-78.
    View in: PubMed
    Score: 0.017
  16. KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet. 2003 May; 72(5):1154-61.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.